Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase ii domec trial)

HIGHLIGHTS

• who: C.C.B. Post from the Radiation, Leiden University Center, Leiden, the Netherlands have published the Article: Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial), in the Journal: (JOURNAL) of September/24,/2021
• what: Assuming a baseline PFS6 of 30% and improved PFS6 of 50%, this study had 80% power at a 5% significance level. This study design introduced limitations.
• how: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the protocol was approved by the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.